Emerging therapeutic targets for the treatment of nicotine addiction

Kenny, Paul J.

doi:10.1586/ecp.09.6

Cited by 6 publications

(2 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…mGlu5-receptor blockade in the nucleus accumbens is effective in preventing relapse to drug seeking as well as neurochemical changes associated with drug reinstatement (Bespalov et al, 2005; Schroeder et al, 2008). mGlu5-receptor NAMs hold promise in the treatment of drug addiction, and AFQ056 is under clinical development for the treatment of tobacco smoking (Kenny, 2009). However, it should be highlighted that mGlu5-receptor blockade increases somatic signs and reward deficits associated with nicotine withdrawal (Liechti and Markou, 2006), suggesting that mGlu5-receptor NAMs should be associated with drugs that lower the reward threshold (e.g., bupropion) in the acute phase of nicotine withdrawal.…”

Section: Detailed Description Of Mglu Receptor Subtypesmentioning

confidence: 99%

Metabotropic glutamate receptors: From the workbench to the bedside

et al. 2011

View full text Add to dashboard Cite

Metabotropic glutamate (mGlu) receptors were discovered in the mid 1980s and originally described as glutamate receptors coupled to polyphosphoinositide hydrolysis. Almost 6500 articles have been published since then, and subtype-selective mGlu receptor ligands are now under clinical development for the treatment of a variety of disorders such as Fragile-X syndrome, schizophrenia, Parkinson’s disease and L-DOPA-induced dyskinesias, generalized anxiety disorder, chronic pain, and gastroesophageal reflux disorder. Prof. Erminio Costa was linked to the early times of the mGlu receptor history, when a few research groups challenged the general belief that glutamate could only activate ionotropic receptors and all metabolic responses to glutamate were secondary to calcium entry. This review moves from those nostalgic times to the most recent advances in the physiology and pharmacology of mGlu receptors, and highlights the role of individual mGlu receptor subtypes in the pathophysiology of human disorders. This article is part of a Special Issue entitled ‘Trends in Neuropharmacology: In Memory of Erminio Costa’.

show abstract

Section: Detailed Description Of Mglu Receptor Subtypesmentioning

confidence: 99%

Metabotropic glutamate receptors: From the workbench to the bedside

et al. 2011

View full text Add to dashboard Cite

show abstract

“…BDNF, which has been shown to be increased in the hippocampus following exercise (Fuss et al, ) and chronic nicotine treatment (Czubak et al, ; Kenny, ; Aydin et al, ), has also been shown to specifically up‐regulate the intracellular pool of α7‐, but not β2*‐, containing nAChRs in cultured hippocampal neurons (Zhou et al, ; Massey et al, ). As a result, we postulated that the observed exercise‐induced region‐specific up‐regulation of α7 nAChR in the brain of nicotine‐treated mice might be mediated by an elevation of BDNF levels.…”

Section: Discussionmentioning

confidence: 99%